VNDA

Over the past six months (April to October 2026), VNDA's stock price was influenced by several events. Vanda reported Q1 and Q2 2026 financial results, with Q2 earnings per share and revenue missing analysts' consensus estimates. The company announced positive Phase III results for HETLIOZ® (tasimelteon) in Delayed Sleep-Wake Phase Disorder. Regulatory milestones included an EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis, subsequent Orphan Designation by the European Commission, and FDA Rare Pediatric Disease Designation for an investigational therapy for Charcot-Marie-Tooth Disease Type 2S. Analyst ratings varied, with HC Wainwright & Co. reiterating a 'Buy,' Zacks Research downgrading to a 'strong sell,' and Oppenheimer initiating coverage with an 'outperform.' Vanda participated in investor conferences such as the H.C. Wainwright 28th Annual Global Investment Conference and the Cantor Global Healthcare Conference. As of October 5, 2026, the share price was $5.03, showing a slight increase of 0.80% over the past year but a 13.94% fall over the last 12 months, with a 52-week range of $4.27 to $9.94.